Brief: GenSight Biologics H1 Net Loss Widens To 10.7 Million Euros

Gensight Biologics SA

28/07/2022 06:38

July 28 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS REPORTS INTERIM FINANCIAL RESULTS FOR
THE
FIRST HALF OF 2022
    * CASH RUNWAY CONFIRMED TO EARLY Q1 2023
    * H1 OPERATING INCOME DECREASED BY 38.2% TO EUR 4.3 MILLION
FROM
EUR 6.9 MILLION OVER PERIOD
    * RESEARCH AND DEVELOPMENT EXPENSES INCREASED BY 23.3%
AMOUNTING
TO EUR 9.9 MILLION IN FIRST HALF OF 2022
    * SALES, MEDICAL AND MARKETING EXPENSES SHARPLY INCREASED BY
76.7%
TO EUR 4.0 MILLION IN FIRST HALF OF 2022
    * CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2022 AMOUNTED TO
EUR
24.1 MILLION
    * H1 NET LOSS EUR 10.7 MLN VS LOSS OF EUR 8.3 MLN YR AGO
    * H1 REVENUES EUR 3.1 MLN VS EUR 5.6 MLN YR AGO

Source text for Eikon:  ID:nBw6wfKNpa 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))